SCL · Stepan Co
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Corporate Expenses non-GAAP | 33.6M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA - Unallocated Corporate non-GAAP | -$33.1M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Cash from Operations | 8.4M | Q2 2026 | — |
|
|
|||
| Consolidated Adjusted EBITDA non-GAAP | $124.1M | Six Months Ended June 30, 2026 | — |
|
|
|||
| EBITDA | 52.7M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Global sales volume | 2% | Three Months Ended June 30, 2026 | — |
|
|
|||
| Net Debt non-GAAP | $533.7M | June 30, 2026 | — |
| Net Debt / (Net Debt + Equity) non-GAAP | 31% | June 30, 2026 | — |
| Organic net sales non-GAAP | 4% | Q1 2026 | — |
| Adjusted EBITDA - Polymers non-GAAP | $76.4M | Full Year 2025 | — |
| Adjusted EBITDA - Specialty Products non-GAAP | $31.5M | Full Year 2025 | — |
| Adjusted EBITDA - Surfactants non-GAAP | $32.1M | Q4 2025 | — |
| Free cash flow non-GAAP | $25.4M | Q4 2025 | — |
| Global sales volume, excluding Philippines asset divestiture | 2% | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Specialty Chemicals — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SCL
this stock
Stepan Co
|
$1.46B | +34.9% | -2.1% | — | 2.6% |
|
LIN
Linde PLC
|
$221.79B | +12.8% | +3.0% | 31.0 | 1.2% |
|
AIQUF
L Air Liquide SA /Fi
|
$122.12B | +4.3% | — | — | 0.0% |
|
SHW
Sherwin Williams Co
|
$84.62B | +9.1% | +2.1% | 32.2 | 2.6% |
|
ECL
Ecolab Inc.
|
$79.62B | +8.8% | +2.2% | 38.1 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SCL | -1.6% | +8.4% | +24.5% | -0.4% | +34.9% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | -1.2% | +5.5% | +12.9% | -3.4% | +22.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.